【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Those Medicines
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Anti-Cancer Kinase Inhibitors
2.1 What are Protein Kinases?
2.2 Protein Kinases in Oncology
2.3 Mechanisms for Kinase Inhibition
2.4 Glossary of Terms
3. Anti-Cancer Kinase Inhibitors: World Market 2014-2024
3.1 The Global Market for Anti-Cancer Kinase Inhibitors in 2013
3.1.1 Leading Anti-Cancer Kinase Inhibitors by Sales, 2013
3.1.2 Leading Companies in the Protein Kinase Inhibitor Market
3.2 World Protein Kinase Inhibitors for Oncology Market: Sales Forecast by Class, 2014-2024
3.2.1 Changing Market Shares by Segment 2014-2024
3.2.2 Leading Anti-Cancer Kinase Inhibitors Manufacturers, 2014-2024
3.3 Bcr-Abl Inhibitors Lead the Protein Kinase Inhibitors for Oncology Market in 2013
3.3.1 Bcr-Abl Kinase Inhibitors: Drivers and Restraints 2014-2024
3.4 Imbruvica and Other Novel Kinase Inhibitors Will Eventually Dominate the Market
3.4.1 Other Kinase Inhibitors: Drivers and Restraints, 2014-2024
4. Leading National and Regional Markets, 2014-2024
4.1 Regional Breakdown of the World Protein Kinase Inhibitors for Drugs Treating Cancer
4.2 World Protein Kinase Inhibitors for Oncology Market: Regional Forecast 2014-2024
4.2.1 How Will Regional Market Shares Change Through to 2024?
4.3 The US Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024
4.4 The US Market: Drivers and Restraints, 2014-2024
4.5 The EU Union Anti-Cancer Kinase Inhibitors Market Forecast, 2014-2024
4.5.1 EU Market: Drivers and Restraints
4.5.2 German Market Forecast, 2014-2024
4.5.3 French Market Forecast, 2014-2024
4.5.4 Italian Market Forecast, 2014-2024
4.5.5 UK Market Forecast, 2014-2024
4.5.6 Spanish Market Forecast, 2014-2024
4.6 The Japanese Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024
4.7 Forecasting Anti-Cancer Kinase Inhibitor Markets in Developing Countries, 2014-2024
4.7.1 Chinese Market Forecast, 2014-2024
4.7.2 Brazilian Market Forecast, 2014-2024
4.7.3 Russian Market Forecast, 2014-2024
4.7.4 Indian Market Forecast, 2014-2024
5. Leading Anti-Cancer Kinase Inhibitors Products, 2014-2024
5.1 Brc-Abl Inhibitors – Managed Care for Chronic Myeloid Leukaemia
5.1.1 Gleevec (imatinib) – Novartis
5.1.1.1 Historic Sales Performance
5.1.1.2 Lifecycle Management, Generic Challenges and Tasigna
5.1.1.3 Gleevec Forecast, 2014-2024
5.1.2 Sprycel (dasatanib) – Bristol-Myers Squibb
5.1.2.1 Patents and Market Exclusivity
5.1.2.2 Historic Sales Performance
5.1.2.3 Sprycel Forecast, 2014-2024
5.1.3 Tasigna (nilotinib) – Novartis
5.1.3.1 Indications and Market Exclusivity
5.1.3.2 Historic Sales Performance
5.1.3.3 Tasigna Forecast, 2014-2024
5.1.4 Bosulif (bosutinib) – Pfizer
5.1.4.1 Bosulif Forecast, 2014-2024
5.1.5 Iclusig (ponatinib) – ARIAD Pharmaceuticals
5.1.5.1 Iclusig Forecast, 2014-2024
5.2 EGFR Inhibitors
5.2.1 Tarceva (erlotinib) – Roche/Astellas
5.2.1.1 Patent Litigation and Market Exclusivity
5.2.1.2 Historic Sales Performance, 2004-2012
5.2.1.3 Tarceva Forecast, 2014-2024
5.2.2 Iressa (gefitinib) – AstraZeneca
5.2.2.1 Historic Sales Performance, 2003-2012
5.2.2.2 Iressa Forecast, 2014-2024
5.2.3 Gilotrif (afatinib) – Boehringer Ingelheim
5.2.3.1 Gilotrif Forecast, 2014-2024
5.3 Angiogenesis Inhibitors
5.3.1 Nexavar (sorafenib) – Bayer/Onyx
5.3.1.1 Historic Sales Performance, 2006-2012
5.3.1.2 Nexavar Forecast, 2014-2024
5.3.2 Sutent (sunitinib) – Pfizer
5.3.2.1 Historic Sales Performance, 2006-2012
5.3.2.2 Sutent Forecast, 2014-2024
5.3.3 Votrient (pazopanib) – GSK
5.3.3.1 Historic Sales Performance, 2010-2012
5.3.3.2 Votrient Forecast, 2014-2024
5.3.4 Inlyta (axitinib) – Pfizer
5.3.4.1 Inlyta Forecast, 2014-2024
5.4 BRAF and MEK Inhibitors
5.4.1 Zelboraf (vemurafenib) – Roche/Daiichi Sankyo
5.4.1.1 Zelboraf Forecast, 2014-2024
5.4.2 Mekinist (trametinib) and Tafinlar (dabrafenib) – GSK
5.4.2.1 Mekinist Forecast, 2014-2024
5.4.2.2 Tafinlar Forecast, 2014-2024
5.5 mTOR Inhibitors
5.5.1 Afinitor (everolimus) – Novartis
5.5.1.1 Patents and Market Exclusivity
5.5.1.2 Historic Sales Performance
5.5.1.3 Afinitor Forecast, 2014-2024
5.5.2 Torisel (temsirolimus) – Pfizer
5.5.2.1 Torisel Forecast, 2014-2024
5.6 Other leading Anticancer Kinase Inhibitors
5.6.1 Imbruvica (ibrutinib) –J&J/Pharmacyclics
5.6.1.1 Imbruvica Forecast, 2014-2024
5.6.2 Jakafi (ruxolitinib) – Novartis/Incyte
5.6.2.1 Jakafi Forecast, 2014-2024
5.6.3 Xalkori (crizotinib) – Pfizer
5.6.3.1 Xalkori Forecast, 2014-2024
5.6.4 Cometriq (cabozantinib) – Exelixis
5.6.4.1 Cometriq Forecast, 2014-2024
5.6.5 Caprelsa (vandetanib) – AstraZeneca
5.6.5.1 Caprelsa Forecast, 2014-2024
5.6.6 Tykerb (lapatinib) – GSK
5.6.6.1 Historic Sales Performance, 2007-2012
5.6.6.2 Tykerb Forecast, 2014-2024
5.6.7 Stivarga (regorafenib) – Bayer
5.6.7.1 Stivarga Forecast, 2014-2024
6. Anti-Cancer Kinase Inhibitors: R&D Pipeline, 2014-2024
6.1 Cyclin-Dependent Kinase 4/6 Inhibitors in Development
6.1.1 Palbociclib – Pfizer
6.1.1.1 Palbociclib Forecast, 2014-2024
6.1.2 LEE-011 – Novartis
6.1.2.1 LEE-011 Forecast, 2014-2024
6.1.3 Bemaciclib (LY2835219) – Eli Lilly
6.1.3.1 Bemaciclib Forecast, 2014-2024
6.2 Anaplastic Lymphoma Kinase (ALK) Inhibitors In Development
6.2.1 Alectinib – Roche
6.2.1.1 Alectinib Forecast, 2014-2024
6.2.2 Ceritinib (LDK378) – Novartis
6.2.2.1 Ceritinib Forecast, 2014-2024
6.2.3 AP26113 – ARIAD
6.3 Bruton’s Tyrosine Kinase and PI3K Inhibitors in Development
6.3.1 Idelalisib – Gilead
6.3.1.1 Idelalisib Forecast, 2014-2024
6.3.2 RG7601 (ABT-199) – Roche/AbbVie
6.3.2.1 ABT-199 Sales Forecast, 2014-2024
6.3.3 IPI-145 – Infinity Pharmaceuticals
6.3.3.1 IPI-145 Forecast, 2014-2024
6.3.4 Buparlisib (BKM120) – Novartis
6.3.4.1 Buparlisib Forecast, 2014-2024
6.3.5 ONO-4059 – Ono Pharmaceuticals
6.3.6 Copanlisib (BAY 80-6946) – Bayer
6.3.7 Pictilisib (GDC-0941) – Roche
6.3.8 BEZ235 – Novartis
6.4 MEK and BRAF Inhibitors in Development
6.4.1 Cobimetinib (GDC-0973) – Roche
6.4.1.1 Cobimetinib Forecast, 2014-2024
6.4.2 Encorafenib (LGX818) – Novartis
6.4.3 Binimetinib (MEK162) – Novartis
6.4.4 Selumetinib (AZD 6244) – AstraZeneca
6.5 Other Kinase Inhibitors in Development
6.5.1 Volasertib – Boehringer Ingelheim
6.5.1.1 Volasertib Forecast, 2014-2024
6.5.2 Neratinib (PB272) – Puma Biotechnology
6.5.3 Tivantinib (ARQ197) – Daiichi Sankyo
6.5.4 Dovotinib (TKI258) – Novartis
6.5.5 Dacomitinib – Pfizer
6.5.6 CO-1686 – Clovis Oncology
7. Qualitative Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
7.1 SWOT Analysis of the Protein Kinase Inhibitors for Oncology Market
7.2 Strengths
7.2.1 Oral Dosage Preferred Over Injection
7.2.2 Stratifying Patients Offers Clinical and Commercial Benefits
7.2.3 Targeted Kinase Inhibitor are Generally Well Tolerated
7.2.4 A Strong Pipeline of Novel Inhibitors Will Drive Market Growth
7.3 Weaknesses
7.3.1 Small Molecule Kinase Inhibitors Will Experience Generic Competition
7.3.2 Competitor Biologics Offer Differentiated Mechanisms of Action
7.3.3 Monoclonal Antibodies are More Specific than Small Molecules
7.4 Opportunities
7.4.1 Novel Targets Identified Through Cancer Genomics
7.4.2 Combination Therapies Bring Additive Benefits
7.4.3 Commercial Success Leveraged by Clinical Benefit
7.5 Threats
7.5.1 Small Molecules Generics Are Easy to Produce
7.5.2 Individual Kinase Targets are Rapidly Becoming Crowded
7.6 STEP Analysis of the Protein Kinase Inhibitors for Oncology Market
7.7 Porter’s Five Forces Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
7.7.1 Rivalry Among Competitors
7.7.2 Threat of New Entrants
7.7.3 Power of Suppliers
7.7.4 Power of Buyers
7.7.5 Threat of Substitutes
8. Research Interview
8.1 Interview with Dr Lawrence Bloch, Chief Finance and Business Officer, Infinity Pharmaceuticals, United States
8.1.1 Positioning a Novel Therapeutic in Blood Cancer Indications
8.1.2 Combining Therapies Offers Significant Benefit to Patients
8.1.3 Potential in Rheumatoid Arthritis and Blood Cancers
9. Conclusions
9.1 The Global Anti-Cancer Kinase Inhibitors Market to 2024
9.1.1 A Robust Pipeline of Innovative Drugs Driving Market Growth
9.2 Leading National Markets for Anti-Cancer Kinase Inhibitors to 2024
【レポート販売概要】
■ タイトル：世界の癌治療用キナーゼ阻害剤市場：Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など■ 英文：Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024
■ 発行日：2014年6月
■ 調査会社：visiongain
■ 商品コード：VISG409052
■ 調査対象地域：グローバル
- トランスペアレント・エレクトロニクスの世界市場：透明ディスプレイ、透明ウインドウ、透明ソーラーパネルAbout transparent electronics Transparent electronics are, essentially, invisible electronic components such as displays, chips, and circuits. They are made of transparent semiconductor materials with unique properties such as wide bandgap and high concentration of free electrons. Transparent electronic is an emerging technology focused on making thin and transparent electronic devices. Technavio’ …
- リアルタイム位置情報システム（RTLS）の世界市場2015-2022According to Stratistics MRC, the Global Real Time Location Systems (RTLS) Market is valued at $967.25 million in 2015 and is expected to grow at a CAGR of 32.14% to reach $6,804.23 million by 2022. Growing government initiatives, huge investments in technology, rising applications into several verticals, and advanced features of the technology are some of the key factors fostering the market grow …
- 世界の感染症治療薬市場：抗菌薬、抗ウイルス薬、抗真菌薬、抗寄生虫薬About Infectious Disease Treatment Infectious diseases can be caused by various pathogenic microorganisms such as bacteria, fungi, parasites, or viruses. These diseases can be transmitted from one individual to another through either direct contact or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on the target organism, anti …
- 世界の急速熱処理装置市場2015The Global Rapid Thermal Processing Equipment Industry Report 2015 is a professional and in-depth study on the current state of the Rapid Thermal Processing Equipment industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Rapid Thermal Processing Equipment market analysis is provided for the international …
- 迅速診断機器の世界市場：血糖値検査、心血管代謝検査、感染症検査、妊娠検査、毒物検査、便潜血検査、凝固検査About Rapid Diagnostics Rapid diagnostic tests are diagnostic assays designed for low-resource settings that provide faster results. These can be carried out either at a patient's bedside or in a clinical setting. These devices are simple to operate and read, have a low cost, and are specific, sensitive, and stable at extreme temperatures. They also provide quick results. Rapid diagnostics is the …
- 脂質異常症（Hyperlipidemia）：グローバル臨床試験レビュー（2014年上半期）Hyperlipidemia Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Hyperlipidemia Global Clinical Trials Review, H1, 2014" provides data on the Hyperlipidemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperlipidemia. It includes an overview of the trial numbers and their recruitment status as per …
- インドの農業の機械化市場2016-2020About Farm Mechanization The global farm mechanization market is largely dependent on agricultural land and farm output. Global agricultural production affects the market substantially as it grows in tandem with the demand for food. However, in various phases, the global agricultural production has slowed down in recent years as the demand for agricultural products has decreased. Recent environmen …
- 赤外線イメージングの世界市場：赤外線レンズシステム、赤外線センサー、赤外線検知器The global infrared imaging market is expected to grow from USD 6.43 Billion in 2015 to USD 11.36 Billion by 2022, at a CAGR of 8.32% between 2016 and 2022. The market is expected to grow substantially due to factors such as surge in demand for infrared imaging in nearly all commercial applications, advantages of LWIR cameras with uncooled technology, and the decreasing cost of IR detectors. IR le …
- 内視鏡検査機器の世界市場予測（～2024年）“The endoscopy equipment market projected to grow at a CAGR of 6.6% during the forecast period (2019–2024).”The global endoscopy equipment market is projected to reach USD 35.2 billion by 2024 from an estimated USD 25.6 billion in 2019 at a CAGR of 6.6% during the forecast period. The key factors driving the growth of this market include growing demand for endoscopy, growing investments, funds, an …
- トルクセンサーの世界市場予測（～2024年）“Torque sensor market to grow at CAGR of 7.9% from 2018 to 2024”The torque sensor market is expected to grow at a CAGR of 7.9%, to reach USD 14.8 billion by 2024 from USD 9.4 billion in 2018. The growth of this market can largely be attributed to factors such as increasing demand for advanced high-performance vehicles, growing importance of torque measurement, and rising demand for torque sensors …
- 自動車テレマティクス市場分析：Analyzing Automotive TelematicsThe advent of any technology always brings with itself an equally strong supporting wave of academic study on the safety, ease of usage and enhancement of convenience of that technology in human usage arena. The application of this approach to automotive usage is known as Automotive Telematics (AT). AT is an integrated platform of mobile, in-vehicle computing and wireless technologies which provid …
- 世界のヘッドマウントディスプレー（HMD）市場動向（2012-2016）TechNavio's analysts forecast the Global Head-mounted Display market to grow at a CAGR of 56.24 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing adoption of head mounted displays in the Consumer Electronics industry. The Global Head-mounted Display market has also been witnessing an increasing number of augmented reality products. Howev …
- 実験室用ロボットの世界市場2017-2021ABSTRACTAbout Laboratory Robotics Laboratory robots empower end-users with robust and faster throughput and enable them to process a large volume of samples in a significantly lesser time than that in manual processing. Analysis of data in research and clinical laboratories is vital for establishing a meaningful result, and this is where robots prove to be highly beneficial in achieving the desire …
- イソシアヌル酸トリグリシジルの世界市場2015Triglycidyl Isocyanurate (TGIC) (CAS 2451-62-9) Market Research Report 2015 aims at providing comprehensive data on Triglycidyl Isocyanurate (TGIC) market globally and regionally (Europe, Asia, North America, Latin America etc.) The report includes Triglycidyl Isocyanurate (TGIC) description, covers its application areas, manufacturing methods, patterns. It captures Triglycidyl Isocyanurate (TGIC) …
- ぶどう膜黒色腫(Uveal Melanoma)：世界の治験レビュー（2015年上半期版）Uveal Melanoma Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Uveal Melanoma Global Clinical Trials Review, H1, 2015" provides data on the Uveal Melanoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Uveal Melanoma. It includes an overview of the trial numbers and their recruitment status as per …
